Epidermal Growth Factor Network Modulation of Immature Central Nervous System Neuronal Functions and the Inhibitory Effects of Ethanol: Relevance to Fetal Alcohol Spectrum Disorder
DOI:
https://doi.org/10.14738/aivp.1402.20058Keywords:
fetal alcohol spectrum disorder, epidermal growth factor, notch, cerebellum, aspartyl-asparaginyl-β-hydroxylase, Transforming growth factor, neuronal migrationAbstract
This study characterizes the effects of epidermal growth factor receptor (EGFR) modulation of growth, metabolic activity, and aspartyl-asparaginyl-β-hydroxylase (ASPH) expression in immature central nervous system neuronal cells (PNET2), crosstalk with insulin/insulin-like growth factor (IGF)/insulin receptor substrate (IRS) and Notch networks, and the effects of ethanol exposure on EGFR-regulated responses. Validation studies were conducted with cerebellar tissue and slice cultures from a fetal alcohol spectrum disorder rat model. PNET2 cell growth, viability, metabolic function, and ASPH expression were supported by EGF, TGF-α, and TGF-β. Those effects were associated with increased tyrosine phosphorylation of EGFR. TGF-β exhibited stimulatory crosstalk with the IGF1 pathway and Notch transcription factors, whereas EGF and TGF-α had inhibitory effects on INSULIN and IGF1 receptor and IRS1 mRNA. Ethanol exposure significantly inhibited EGF, TGF-α, and TGF-β-stimulated pY-EGFR, PCNA, and ASPH expression in PNET2 and rat cerebellar slice cultures. The findings herein establish that EGFR pathways regulate critical functions in immature CNS neuronal cells, including ASPH, which mediates cell migration during development. Crosstalk between EGF or TGF-α and insulin/IGF networks was largely inhibitory, whereas between TGF-β and insulin/IGF or Notch networks, the crosstalk was stimulatory. Ethanol’s prominent inhibitory effects on EGFR networks and activation of ASPH likely contribute to the FASD-associated impairments in cerebellar development and function. Therapeutic measures that fortify EGFR signaling through Notch and ASPH may reduce the adverse effects of prenatal alcohol exposure on the brain.
References
Del Campo M, Jones KL (2017) A review of the physical features of the fetal alcohol spectrum disorders. Eur J Med Genet 60, 55–64.
Riley EP, McGee CL (2005) Fetal alcohol spectrum disorders: an overview with emphasis on changes in brain and behavior. Exp Biol Med (Maywood) 230, 357–365.
Roozen S, Black D, Peters GY, Kok G, Townend D, Nijhuis JG, Koek GH, Curfs LM (2016) Fetal Alcohol Spectrum Disorders (FASD): an Approach to Effective Prevention. Curr Dev Disord Rep
Gomez DA, Abdul-Rahman OA (2021) Fetal alcohol spectrum disorders: current state of diagnosis and treatment. Curr Opin Pediatr 33, 570–575.
Akison LK, Hayes N, Vanderpeet C, Logan J, Munn Z, Middleton P, Moritz KM, Reid N, Australian Fasd Guidelines Development Group obotAFGC (2024) Prenatal alcohol exposure and associations with physical size, dysmorphology and neurodevelopment: a systematic review and meta-analysis. BMC Med 22, 467.
Valenzuela CF, Reid NM, Blanco BB, Carlson VL, Do AB (2025) Impact of Developmental Alcohol Exposure on the Thalamus. Adv Exp Med Biol 1473, 67–92.
Nogales F, Jotty K, Pascual-Vaca D, Gallego-Lopez MDC, Carreras O, Ojeda ML (2025) Rat models of fetal alcohol spectrum disorders for studying the critical role of cerebellar damage: A scoping review. Alcohol Clin Exp Res (Hoboken) 49, 1855–1876.
Granato A (2025) Defects of Cortical Microcircuits Following Early Exposure to Alcohol. Adv Exp Med Biol 1473, 3–13.
Gao J, Liu B, Chen H, Xu P, Guo X, Yao D, Li X, Wang T, Wang Y, Yao H, Qiao S, Yuan J, Liu Y (2026) The role of DNA methylation in alcohol-mediated neurodevelopmental toxicity. Toxicology 519, 154315.
Licheri V, Brigman JL (2021) Altering Cell-Cell Interaction in Prenatal Alcohol Exposure Models: Insight on Cell-Adhesion Molecules During Brain Development. Front Mol Neurosci 14,
Oskera L, Charlet-Briart M, Tielens S, Nguyen L, Laguesse S (2026) Impact of Prenatal Alcohol Exposure on Cerebral Cortex Development. Adv Exp Med Biol 1500, 143–181.
Basavarajappa BS, Subbanna S (2023) Synaptic Plasticity Abnormalities in Fetal Alcohol Spectrum Disorders. Cells 12.
Guizzetti M, Zhang X, Goeke C, Gavin DP (2014) Glia and neurodevelopment: focus on fetal alcohol spectrum disorders. Front Pediatr 2, 123. Scholar Publishing
Guizzetti M, Mangieri RA, Ezerskiy LA, Hashimoto JG, Bajo M, Farris SP, Homanics GE, Lasek AW, Mayfield RD, Messing RO, Roberto M (2026) Astrocytes and Alcohol Throughout the Lifespan. Biol Psychiatry 99, 9–20.
Mathews E, Dewees K, Diaz D, Favero C (2021) White matter abnormalities in fetal alcohol spectrum disorders: Focus on axon growth and guidance. Exp Biol Med (Maywood) 246, 812–
Darbinian N, Selzer ME (2022) Oligodendrocyte pathology in fetal alcohol spectrum disorders. Neural Regen Res 17, 497–502.
Roozen S, Ehrhart F (2023) Fetal alcohol spectrum disorders and the risk of crime. Handb Clin Neurol 197, 197–204.
Tong M, Andreani T, Krotow A, Gundogan F, de la Monte SM (2016) Potential Contributions of the Tobacco Nicotine-Derived Nitrosamine Ketone to White Matter Molecular Pathology in Fetal Alcohol Spectrum Disorder. Int J Neurol Brain Disord 3, 1–12.
Ramsay M (2010) Genetic and epigenetic insights into fetal alcohol spectrum disorders. Genome Med 2, 27.
de la Monte SM, Tong M, Bowling N, Moskal P (2011) si-RNA inhibition of brain insulin or insulin-like growth factor receptors causes developmental cerebellar abnormalities: relevance to fetal alcohol spectrum disorder. Mol Brain 4, 13.
Smith SM (2025) Nonconceptus Mechanisms of Prenatal Alcohol Exposure That Disrupt Embryo-Fetal Development: An Integrative View. Alcohol Res 45, 07.
de la Monte SM, Wands JR (2005) Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. Journal of Alzheimer's disease : JAD 7, 45–61.
de la Monte SM, Sutherland G (2025) Dual Stages of Alcohol-Related Cerebral White Matter Degeneration Reviewed: Early-Stage Stress/Neuroinflammation Versus Late-Stage Impaired Insulin/IGF Signaling Through Akt-mTOR-Review. ASN Neuro 17, 2573965.
Yoon MS (2017) The Role of Mammalian Target of Rapamycin (mTOR) in Insulin Signaling. Nutrients 9, 1176.
Querfurth H, Lee HK (2021) Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration. Mol Neurodegener 16, 44.
Carter JJ, Tong M, Silbermann E, Lahousse SA, Ding FF, Longato L, Roper N, Wands JR, de la Monte SM (2008) Ethanol impaired neuronal migration is associated with reduced aspartylasparaginyl-beta-hydroxylase expression. Acta Neuropathol 116, 303–315.
Gundogan F, Elwood G, Longato L, Tong M, Feijoo A, Carlson RI, Wands JR, de la Monte SM (2008) Impaired placentation in fetal alcohol syndrome. Placenta 29, 148–157.
de la Monte SM, Tong M, Carlson RI, Carter JJ, Longato L, Silbermann E, Wands JR (2009) Ethanol inhibition of aspartyl-asparaginyl-beta-hydroxylase in fetal alcohol spectrum disorder: Potential link to the impairments in central nervous system neuronal migration. Alcohol 43,
Tong M, Gonzalez-Navarrete H, Kirchberg T, Gotama B, Yalcin EB, Kay J, de la Monte SM (2017) Ethanol-Induced White Matter Atrophy Is Associated with Impaired Expression of Aspartyl-Asparaginyl-beta-Hydroxylase (ASPH) and Notch Signaling in an Experimental Rat Model. J Drug Alcohol Res 6.
Gundogan F, Tong M, M. de la Monte S (2024) Association between dietary soy prevention of fetal alcohol spectrum disorder and normalization of placental insulin and insulin-like growth Scholar Publishing factor signaling networks and downstream effector molecule expression. Gene & Protein in Disease 3, 3113.
Lavaissiere L, Jia S, Nishiyama M, de la Monte S, Stern AM, Wands JR, Friedman PA (1996) Overexpression of human aspartyl(asparaginyl)beta-hydroxylase in hepatocellular carcinoma and cholangiocarcinoma. J Clin Invest 98, 1313–1323.
Ince N, de la Monte SM, Wands JR (2000) Overexpression of human aspartyl (asparaginyl) beta-hydroxylase is associated with malignant transformation. Cancer Res 60, 1261–1266.
Sepe PS, Lahousse SA, Gemelli B, Chang H, Maeda T, Wands JR, de la Monte SM (2002) Role of the aspartyl-asparaginyl-beta-hydroxylase gene in neuroblastoma cell motility. Lab Invest 82,
Maeda T, Sepe P, Lahousse S, Tamaki S, Enjoji M, Wands JR, de la Monte SM (2003) Antisense oligodeoxynucleotides directed against aspartyl (asparaginyl) beta-hydroxylase suppress migration of cholangiocarcinoma cells. J Hepatol 38, 615–622.
Silbermann E, Moskal P, Bowling N, Tong M, de la Monte SM (2010) Role of aspartyl-(asparaginyl)-beta-hydroxylase mediated notch signaling in cerebellar development and function. Behav Brain Funct 6, 68.
Cantarini MC, de la Monte SM, Pang M, Tong M, D'Errico A, Trevisani F, Wands JR (2006) Aspartyl-asparagyl beta hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms. Hepatology 44, 446–
Jia S, VanDusen WJ, Diehl RE, Kohl NE, Dixon Ra, Elliston KO, Stern aM, Friedman Pa (1992) cDNA cloning and expression of bovine aspartyl (asparaginyl) beta-hydroxylase. J Biol Chem
Lawton M, Tong M, Gundogan F, Wands JR, de la Monte SM (2010) Aspartyl-(asparaginyl) betahydroxylase, hypoxia-inducible factor-alpha and Notch cross-talk in regulating neuronal motility. Oxidative medicine and cellular longevity 3, 347–356.
Borgas DL, Gao JS, Tong M, Roper N, de la Monte SM (2015) Regulation of Aspartyl-(Asparaginyl)-beta-Hydroxylase Protein Expression and Function by Phosphorylation in Hepatocellular Carcinoma Cells. J Nat Sci 1.
Borgas DL, Gao JS, Tong M, de la Monte SM (2015) Potential Role of Phosphorylation as a Regulator of Aspartyl-(asparaginyl)-beta-hydroxylase: Relevance to Infiltrative Spread of Human Hepatocellular Carcinoma. Liver Cancer 4, 139–153.
Fife M, Tong M, Das B, Rodriguez R, Chokkalingam P, Carlson RI, de la Monte SM (2025) Chondrosarcoma: Multi-Targeting Therapeutic Effects of Doxorubicin, BEZ235, and the Small Molecule Aspartyl-Asparaginyl-beta-hydroxylase Inhibitor SMI1182. Cancers (Basel) 17, 1671.
Estrada C, Villalobo A (2006) Epidermal Growth Factor Receptor in the Adult Brain. In The Cell Cycle in the Central Nervous System, Janigro D, ed. Humana Press Inc, Totowa, NJ, pp.
Tito C, Masciarelli S, Colotti G, Fazi F (2025) EGF receptor in organ development, tissue homeostasis and regeneration. J Biomed Sci 32, 24.
Xian CJ, Zhou XF (1999) Roles of transforming growth factor-alpha and related molecules in the nervous system. Mol Neurobiol 20, 157–183.
Sadeghzadeh S, Ebrahimi R, Zareiye A, Meshkin A, Aghabozorgi R, Lotfi M, Ghanbari F, Shahcheraghi SH, Aghili ZS (2025) Targeting TGF-beta signaling in glioblastoma: therapeutic implications and novel drug development strategies. Brain Tumor Pathol 42, 105–120. Scholar Publishing
Kaminska B, Wesolowska A, Danilkiewicz M (2005) TGF beta signalling and its role in tumour pathogenesis. Acta Biochim Pol 52, 329–337.
Romano R, Bucci C (2020) Role of EGFR in the Nervous System. Cells 9, 1887.
Dinchuk JE, Henderson NL, Burn TC, Huber R, Ho SP, Link J, O'Neil KT, Focht RJ, Scully MS, Hollis JM, Hollis GF, Friedman PA (2000) Aspartyl beta -hydroxylase (Asph) and an evolutionarily conserved isoform of Asph missing the catalytic domain share exons with junctin. J Biol Chem 275, 39543–39554.
Chung W, Kim M, de la Monte S, Longato L, Carlson R, Slagle BL, Dong X, Wands JR (2016) Activation of signal transduction pathways during hepatic oncogenesis. Cancer Lett 370, 1–9.
Dong X, Lin Q, Aihara A, Li Y, Huang CK, Chung W, Tang Q, Chen X, Carlson R, Nadolny C, Gabriel G, Olsen M, Wands JR (2015) Aspartate beta-Hydroxylase expression promotes a malignant pancreatic cellular phenotype. Oncotarget 6, 1231–1248.
Sturla LM, Tong M, Hebda N, Gao J, Thomas JM, Olsen M, de la Monte SM (2016) Aspartatebeta-hydroxylase (ASPH): A potential therapeutic target in human malignant gliomas. Heliyon 2, e00203.
Andreani T, Tong M, Gundogan F, Silbermann E, de la Monte SM (2016) Differential Effects of 3rd Trimester-Equivalent Binge Ethanol and Tobacco-Specific Nitrosamine Ketone Exposures on Brain Insulin Signaling in Adolescence. J Diabetes Relat Disord 1, 105–114.
de la Monte SM, Tong M, Delikkaya B (2023) Differential Early Mechanistic Frontal Lobe Responses to Choline Chloride and Soy Isoflavones in an Experimental Model of Fetal Alcohol Spectrum Disorder. Int J Mol Sci 24, 7595.
de la Monte SM, Ganju N, Banerjee K, Brown NV, Luong T, Wands JR (2000) Partial rescue of ethanol-induced neuronal apoptosis by growth factor activation of phosphoinositol-3-kinase. Alcohol Clin Exp Res 24, 716–726.
Feoktistova M, Geserick P, Leverkus M (2016) Crystal Violet Assay for Determining Viability of Cultured Cells. Cold Spring Harb Protoc 2016, pdb prot087379.
Stern-Straeter J, Bonaterra GA, Hormann K, Kinscherf R, Goessler UR (2009) Identification of valid reference genes during the differentiation of human myoblasts. BMC Mol Biol 10, 66.
Le T, Tong M, Nguyen V, de la Monte SM (2013) PPAR Agonist Rescue of Ethanol-Impaired Brain Insulin Signaling: Cerebellar Slice Culture Model. Journal of Drug and Alcohol Research
Shaughness M, Acs D, Brabazon F, Hockenbury N, Byrnes KR (2020) Role of Insulin in Neurotrauma and Neurodegeneration: A Review. Front Neurosci 14, 547175.
McGinnis K, Ku GM, VanDusen WJ, Fu J, Garsky V, Stern aM, Friedman Pa (1996) Site-directed mutagenesis of residues in a conserved region of bovine aspartyl (asparaginyl) betahydroxylase: evidence that histidine 675 has a role in binding Fe2+. Biochemistry 35, 3957–
Tong M, Gao JS, Borgas D, de la Monte SM (2013) Phosphorylation Modulates Aspartyl-(Asparaginyl)-beta Hydroxylase Protein Expression, Catalytic Activity and Migration in Human Immature Neuronal Cerebellar Cells. Cell Biol (Henderson, NV) 6.
de la Monte SM, Tamaki S, Cantarini MC, Ince N, Wiedmann M, Carter JJ, Lahousse SA, Califano S, Maeda T, Ueno T, D'Errico A, Trevisani F, Wands JR (2006) Aspartyl-(asparaginyl)-beta-hydroxylase regulates hepatocellular carcinoma invasiveness. J Hepatol 44, 971–983. Scholar Publishing
Lahousse SA, Carter JJ, Xu XJ, Wands JR, de la Monte SM (2006) Differential growth factor regulation of aspartyl-(asparaginyl)-beta-hydroxylase family genes in SH-Sy5y human neuroblastoma cells. BMC Cell Biol 7, 41.
de la Monte SM, Wands JR (2010) Role of central nervous system insulin resistance in fetal alcohol spectrum disorders. J Popul Ther Clin Pharmacol 17, e390–404.
Son AI, Mohammad S, Sasaki T, Ishii S, Yamashita S, Hashimoto-Torii K, Torii M (2020) Dual Role of Rbpj in the Maintenance of Neural Progenitor Cells and Neuronal Migration in Cortical Development. Cereb Cortex 30, 6444–6457.
Wiszniak S, Schwarz Q (2019) Notch signalling defines dorsal root ganglia neuroglial fate choice during early neural crest cell migration. BMC Neurosci 20, 21.
Yang Z, Li PF, Chen RC, Wang J, Wang S, Shen Y, Wu X, Fang B, Cheng X, Xiong ZQ (2017) ADAM10-Initiated Release of Notch Intracellular Domain Regulates Microtubule Stability and Radial Migration of Cortical Neurons. Cereb Cortex 27, 919–932.
Aujla PK, Bora A, Monahan P, Sweedler JV, Raetzman LT (2011) The Notch effector gene Hes1 regulates migration of hypothalamic neurons, neuropeptide content and axon targeting to the pituitary. Dev Biol 353, 61–71.
de la Monte SM, Elgas E, Tong M, Delikkaya B, Yang Y (2023) Differential rescue effects of choline chloride and soy isolate on metabolic dysfunction in immature central nervous system neurons: Relevance to fetal alcohol spectrum disorder. Diabetes Manag 13, 107–118.
Zabala V, Silbermann E, Re E, Andreani T, Tong M, Ramirez T, Gundogan F, de la Monte SM (2016) Potential Co-Factor Role of Tobacco Specific Nitrosamine Exposures in the Pathogenesis of Fetal Alcohol Spectrum Disorder. Gynecol Obstet Res 2, 112–125.
Leung ECH, Jain P, Michealson MA, Choi H, Ellsworth-Kopkowski A, Valenzuela CF (2024) Recent breakthroughs in understanding the cerebellum's role in fetal alcohol spectrum disorder: A systematic review. Alcohol 119, 37–71.
de la Monte SM, Tong M, Ziplow J, Mark P, Van S, Nguyen VA (2025) Impact of Prenatal Dietary Soy on Cerebellar Neurodevelopment and Function in Experimental Fetal Alcohol Spectrum Disorder. Nutrients 17, 812.
Halder S, Basu S, Lall SP, Ganti AK, Batra SK, Seshacharyulu P (2023) Targeting the EGFR signaling pathway in cancer therapy: What's new in 2023? Expert Opin Ther Targets 27, 305–
Du Y, Karatekin F, Wang WK, Hong W, Boopathy GTK (2025) Cracking the EGFR code: Cancer biology, resistance mechanisms, and future therapeutic frontiers. Pharmacol Rev 77, 100076.
Purow BW, Sundaresan TK, Burdick MJ, Kefas BA, Comeau LD, Hawkinson MP, Su Q, Kotliarov Y, Lee J, Zhang W, Fine HA (2008) Notch-1 regulates transcription of the epidermal growth factor receptor through p53. Carcinogenesis 29, 918–925.
Hu T, Li C (2010) Convergence between Wnt-beta-catenin and EGFR signaling in cancer. Mol Cancer 9, 236.
Tripurani SK, Wang Y, Fan YX, Rahimi M, Wong L, Lee MH, Starost MF, Rubin JS, Johnson GR (2018) Suppression of Wnt/beta-catenin signaling by EGF receptor is required for hair follicle development. Mol Biol Cell 29, 2784–2799.
Luu M, Sabo E, de la Monte SM, Greaves W, Wang J, Tavares R, Simao L, Wands JR, Resnick MB, Wang L (2009) Prognostic value of aspartyl (asparaginyl)-beta-hydroxylase/humbug expression in non-small cell lung carcinoma. Human pathology 40, 639–644. Scholar Publishing
Wang J, de la Monte SM, Sabo E, Kethu S, Tavares R, Branda M, Simao L, Wands JR, Resnick MB (2007) Prognostic value of humbug gene overexpression in stage II colon cancer. Human pathology 38, 17–25.
Kato M, Mizuguchi M, Takashima S (1995) Developmental changes of epidermal growth factorlike immunoreactivity in the human fetal brain. J Neurosci Res 42, 486–492.
Kornblum HI, Hussain RJ, Bronstein JM, Gall CM, Lee DC, Seroogy KB (1997) Prenatal ontogeny of the epidermal growth factor receptor and its ligand, transforming growth factor alpha, in the rat brain. J Comp Neurol 380, 243–261.
Hamada K, Lasek AW (2020) Receptor Tyrosine Kinases as Therapeutic Targets for Alcohol Use Disorder. Neurotherapeutics 17, 4–16.
Zhou FC, Zhao Q, Liu Y, Goodlett CR, Liang T, McClintick JN, Edenberg HJ, Li L (2011) Alteration of gene expression by alcohol exposure at early neurulation. BMC Genomics 12,
Irvin DK, Zurcher SD, Nguyen T, Weinmaster G, Kornblum HI (2001) Expression patterns of Notch1, Notch2, and Notch3 suggest multiple functional roles for the Notch-DSL signaling system during brain development. J Comp Neurol 436, 167–181.
Weller M, Krautler N, Mantei N, Suter U, Taylor V (2006) Jagged1 ablation results in cerebellar granule cell migration defects and depletion of Bergmann glia. Dev Neurosci 28,
Gaiano N (2008) Strange bedfellows: Reelin and Notch signaling interact to regulate cell migration in the developing neocortex. Neuron 60, 189–191.
de la Monte SM, Tong M, Ziplow J, Mark P, Van S, Nguyen VA (2025) Dietary Soy Preserves Cognitive Function in Experimental Fetal Alcohol Spectrum Disorder: Role of Increased Signaling through Notch and Gonadotropin Releasing Hormone Networks. J Behav Brain Sci 15,
Reading CL, Flores-Riveros J, Stickney DR, Frincke JM (2013) An anti-inflammatory sterol decreases obesity-related inflammation-induced insulin resistance and metabolic dysregulation. Mediators Inflamm 2013, 814989.
Reading CL, Frincke JM, White SK (2012) Molecular targets for 17alpha-ethynyl-5-androstene-3beta,7beta,17beta-triol, an anti-inflammatory agent derived from the human metabolome. PLoS One 7, e32147.
Reading CL, Stickney DR, Flores-Riveros J, Destiche DA, Ahlem CN, Cefalu WT, Frincke JM (2013) A synthetic anti-inflammatory sterol improves insulin sensitivity in insulin-resistant obese impaired glucose tolerance subjects. Obesity (Silver Spring) 21, E343–349.
Wang T, Villegas S, Huang Y, White SK, Ahlem C, Lu M, Olefsky JM, Reading C, Frincke JM, Alleva D, Flores-Riveros J (2010) Amelioration of glucose intolerance by the synthetic androstene HE3286: link to inflammatory pathways. The Journal of pharmacology and experimental therapeutics 333, 70–80.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Ming Tong, Suzanne M. de la Monte
This work is licensed under a Creative Commons Attribution 4.0 International License.
